ArticleJournal of biological engineering2026
Harmine-loaded PCL/PVA multilayer nanofibers for targeted pancreatic cancer therapy.
Article in Journal of biological engineering, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPancreatic cancer remains one of the deadliest malignancies because of late diagnosis, rapid metastasis, and poor response to conventional therapies. Localized drug delivery systems based on electrospun nanofibers may improve therapeutic outcomes by enabling sustained local drug release while minimizing systemic toxicity. This study developed harmine (HAR)-loaded multilayer nanofibers using polycaprolactone (PCL) and polyvinyl alcohol (PVA) and evaluated their physicochemical characteristics and anti-cancer effects against ASPC-1 pancreatic cancer cells.
resultsBilayer and trilayer HAR-loaded nanofibers were successfully fabricated with uniform, bead-free morphology. Morphology was characterized by FE-SEM, and drug incorporation was confirmed by FTIR analysis. The multilayer architecture demonstrated favorable swelling behavior, controlled degradation, and regulated water vapor transmission. Drug release studies showed an initial burst release (~ 16% within 6 h), followed by sustained HAR release reaching approximately 68% over 72 h. Blank nanofibers exhibited high biocompatibility (> 97% cell viability). Compared with free HAR, HAR-loaded nanofibers (NFs) significantly enhanced anti-cancer efficacy and achieved nearly complete suppression of viability in ASPC-1 cells after 72 h. Functional analyses demonstrated substantial inhibition of cell migration and colony formation. Molecular evaluation revealed significant apoptosis induction through upregulation of BAX and CASP3 and downregulation of BCL-2, with the PCL/PVAHAR formulation showing the strongest response (BAX ≈ 4.8-fold, CASP3 ≈ 3.9-fold, BCL-2 ≈ 0.35-fold; BAX/BCL-2 ratio ≈ 13.7). STRING analysis further supported the involvement of apoptosis-associated signaling pathways.
conclusionsHAR-loaded PCL/PVA nanofibers provide an effective localized drug-delivery platform with sustained release and enhanced anti-pancreatic-cancer activity compared with free HAR. These findings support the further development of this system as a potential implantable therapeutic strategy for post-resection pancreatic cancer management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.